Amira achieves two clinical development milestones in FLAP program for asthma

NewsGuard 100/100 Score
Jul 19 2010

"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

These milestones are related to the successful progression of the program to Phase 2 studies, which explore the use of the Amira discovered FLAP inhibitor in patients suffering from asthma.  

"These milestones demonstrate the success of our partnership with GSK as well as the need for new therapies for asthma sufferers." said Hari Kumar, Chief Business Officer.  "These milestone payments enable Amira to continue to fund our highly productive research and development opportunities well into the future."

Source:

Amira Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Asthma attacks cause airway damage beyond inflammation, research shows
Understanding the unique types and triggers of asthma
Multiple atmospheric pollutants may be triggering asthma symptoms among children
USC study unveils iron as key driver of lung inflammation in allergic asthma
Newly discovered cause for asthma sparks hope for treatment
SARS-COV-2 infection not linked to increased risk of asthma development in pediatric patients
Air pollution in Austin neighborhoods raises asthma-related ER visits, study finds
Higher zinc intake linked to lower asthma risk in overweight kids

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Second-hand vape smoke linked to more asthma symptoms in kids